OptiNose (OPTN) Q2 2024 earnings summary

Executive summary

• XHANCE received FDA approval for chronic sinusitis (including chronic rhinosinusitis without nasal polyps), expanding its addressable market up to 10 times and making it the first and only approved drug for this indication.

• Early launch efforts are focused on prescriber education, central pharmacy hub optimization, and expanding access through major formularies, with positive initial engagement from prescribers and payers.

• A $55–$55.3 million registered direct offering in May 2024 and debt agreement revisions provide sufficient liquidity to fund operations and service debt through 2025.

• XHANCE was added to Express Scripts' national formularies, expanding preferred coverage to over 24 million lives and supporting broader market penetration.

• The company realigned sales territories and transitioned to a central pharmacy hub model to support anticipated growth.

Financial highlights

• Q2 2024 XHANCE net revenue was $20.5 million, up 5% year-over-year; first half 2024 net revenue was $35.4 million, up 13% year-over-year.

• Average net revenue per prescription in Q2 2024 was $309, a 44% increase year-over-year; first half 2024 average was $269, up 51% year-over-year.

• Net loss for Q2 2024 was $7.6 million ($0.07 per diluted share); six-month net loss was $21.6 million ($0.17 per diluted share).

• Cash and cash equivalents as of June 30, 2024 were $91.4 million; debt outstanding was $130 million.

• SG&A plus R&D expenses in Q2 2024 were $25.1 million, up $4 million year-over-year; first half 2024 expenses were $46.8 million, up $1 million year-over-year.

Outlook and guidance

• Full year 2024 XHANCE net revenue guidance narrowed to $85–$90 million, representing 20–27% growth over 2023.

• Expected average net revenue per prescription for 2024 raised to at least $250, up from $230 previously.

• Operating expenses for 2024 expected between $95–$101 million, with $6 million in stock-based compensation.

• Positive operating income projected for full year 2025; cash and equivalents expected to fund operations and debt service through 2025.

• Current sales footprint and incremental investment expected to drive peak net revenue of at least $300 million.